

Table 3. Pulmonary Toxicity Associated with Alkylating Agents

Alkylating Agents	Clinical syndromes	Potential risk factors
Busulfan	<ul style="list-style-type: none"> • Late onset progressive pulmonary fibrosis 	<ul style="list-style-type: none"> • cumulative dose (threshold approximately 500 mg) • concurrent treatment with other alkylating agents • concurrent therapeutic radiation
Cyclophosphamide	<ul style="list-style-type: none"> • Acute interstitial pneumonitis • Late interstitial pneumonitis/ pulmonary fibrosis 	<ul style="list-style-type: none"> • concurrent treatment with other drugs with potential pulmonary toxicity
Other agents (chlorambucil, melphalan, ifosfamide)	<ul style="list-style-type: none"> • Interstitial pneumonitis 	